Access Pharmaceuticals to present two oncology posters at CPR Conference ACCESS PHARMACEUTICALS.

For information on the conference, please visit:.. Access Pharmaceuticals to present two oncology posters at CPR Conference ACCESS PHARMACEUTICALS, INC. , a biopharmaceutical business leveraging its proprietary drug-delivery platforms to build up treatments in regions of oncology, cancer supportive diabetes and treatment, announced that two oncology posters are getting shown this week at the Improvements in Cancer Avoidance and Research Meeting at the Austin Convention Center in Austin, TX. Related StoriesLilly, ImaginAb partner to review potential novel T-cell-based immuno-oncology therapiesNew guidance declaration on palliative treatment to be presented at 2015 Palliative Care in Oncology SymposiumResearchers determine new target for novel immune-oncology remedies We are very happy to be one of them year’s Innovations in Tumor Prevention and Research Meeting as the team’s research in both programs support a substantial opportunity in treating several cancers, said David Nowotnik, Senior VP of Development and Study, Access Pharmaceuticals, Inc.Some of the additional trials focused on people who’d give up statins due to the side effects. However, that doesn’t mean the brand new drugs are completely safe and sound. Martin said the primary concern that has arisen in trials of the new drugs is the potential for ‘neurocognitive effects.’ For instance, some scholarly study individuals reported problems such as confusion and trouble paying attention. But, Martin said, it isn’t clear yet if the PCSK9 inhibitors are in fact the cause. For the history review, researchers led by Dr. Eliano Navarese, of Heinrich Heine University in Dusseldorf, Germany, pooled the results of 24 scientific trials involving a lot more than 10,000 patients. Some compared a PCSK9 inhibitor to a placebo , while some used the cholesterol medication ezetimibe for assessment.